HK Stock Market Move | CARSGEN-B(02171) up by more than 6% Claudin18.2 CAR-T shureosumab injection included in breakthrough therapy drug variety

CARSGEN-B(02171) rose by over 6%, as of the time of writing, it increased by 6.14% to 16.94 Hong Kong dollars, with a turnover of 55.042 million Hong Kong dollars. In terms of news, Keji Pharmaceutical announced this morning that its independently developed Shu Rui Ji Ao Lun Sai injection (research code: CT041) has been included in the list of breakthrough therapeutic drug varieties by the National Medical Products Administration Drug Evaluation Center. The proposed indication is for advanced gastric/esophageal-gastric junction adenocarcinoma expressing Claudin18.2 that has failed at least second-line treatment in the past. The company expects to submit a new drug application for Shu Rui Ji Ao Lun Sai injection to the National Medical Products Administration in the first half of 2025. Guoyuan International previously pointed out that the company is an innovative research and development-driven biotechnology company, focusing on innovative CAR-T cell therapy. Its universal CAR-T technology is leading, breakthroughs have been made in CAR-T therapy for solid tumors, and CT041 for treating gastric cancer is expected to submit an NDA in the first half of 2025. The company already has a listed product, Saikai Ze, promoted by Huadong Medicine, and is about to ramp up production.